The man with 2 hearts: 25 years from heterotopic to orthotopic heart transplantation

Elizabeth L. Godfrey, Michael L. Kueht, Abbas Rana, O. H. Frazier

Research output: Contribution to journalArticle

Abstract

Substantial technological advances in mechanical circulatory support have caused a shift in the management of end-stage heart failure. From the 1970s through the 1990s, heterotopic heart transplantation was routinely performed in patients in whom orthotopic transplantation was likely to fail. Heterotopic heart transplantation is now performed less often because modern mechanical circulatory assist devices are routinely used as bridges to orthotopic transplantation; regardless, the operation has helped numerous patients who would not otherwise have received adequate allografts. We describe the case of a man with idiopathic nonischemic cardiomyopathy who, at age 17, was given an ABO-and size-matched heterotopic allograft that was a complete human leukocyte antigen mismatch. The graft functioned normally for 20 years until the patient had a myocardial infarction that necessitated placement of a coronary artery stent. Subsequent treatments involved many interventions, including insertion of an intra-aortic balloon pump, medical therapy for heart failure, implantation of a total artificial heart, and, ultimately, orthotopic transplantation. To our knowledge, our patient is the longest surviving recipient of a heterotopic heart transplant, with a remarkable 25-year graft survival despite poor histocompatibility and an almost complete lack of native heart function. The strategies used for his treatment make him a living case study that can add valuable information to the history of cardiac support.

Original languageEnglish (US)
Pages (from-to)199-202
Number of pages4
JournalTexas Heart Institute Journal
Volume46
Issue number3
DOIs
StatePublished - Jun 2019

Fingerprint

Heart Transplantation
Heterotopic Transplantation
Transplantation
Allografts
Heart Failure
Transplants
Artificial Heart
Histocompatibility
Graft Survival
HLA Antigens
Cardiomyopathies
Stents
Coronary Vessels
Therapeutics
History
Myocardial Infarction
Equipment and Supplies

Keywords

  • Follow-up studies
  • Graft survival
  • Heart failure/surgery
  • Heart trans-plantation/methods/physiol-ogy
  • Heterotopic
  • HLA antigens/analysis
  • Reoperation
  • Survival analysis
  • Time factors
  • Transplant recipients
  • Transplantation
  • Treatment outcome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The man with 2 hearts : 25 years from heterotopic to orthotopic heart transplantation. / Godfrey, Elizabeth L.; Kueht, Michael L.; Rana, Abbas; Frazier, O. H.

In: Texas Heart Institute Journal, Vol. 46, No. 3, 06.2019, p. 199-202.

Research output: Contribution to journalArticle

Godfrey, Elizabeth L. ; Kueht, Michael L. ; Rana, Abbas ; Frazier, O. H. / The man with 2 hearts : 25 years from heterotopic to orthotopic heart transplantation. In: Texas Heart Institute Journal. 2019 ; Vol. 46, No. 3. pp. 199-202.
@article{8bad7f7ba63b4072af303547943b5f92,
title = "The man with 2 hearts: 25 years from heterotopic to orthotopic heart transplantation",
abstract = "Substantial technological advances in mechanical circulatory support have caused a shift in the management of end-stage heart failure. From the 1970s through the 1990s, heterotopic heart transplantation was routinely performed in patients in whom orthotopic transplantation was likely to fail. Heterotopic heart transplantation is now performed less often because modern mechanical circulatory assist devices are routinely used as bridges to orthotopic transplantation; regardless, the operation has helped numerous patients who would not otherwise have received adequate allografts. We describe the case of a man with idiopathic nonischemic cardiomyopathy who, at age 17, was given an ABO-and size-matched heterotopic allograft that was a complete human leukocyte antigen mismatch. The graft functioned normally for 20 years until the patient had a myocardial infarction that necessitated placement of a coronary artery stent. Subsequent treatments involved many interventions, including insertion of an intra-aortic balloon pump, medical therapy for heart failure, implantation of a total artificial heart, and, ultimately, orthotopic transplantation. To our knowledge, our patient is the longest surviving recipient of a heterotopic heart transplant, with a remarkable 25-year graft survival despite poor histocompatibility and an almost complete lack of native heart function. The strategies used for his treatment make him a living case study that can add valuable information to the history of cardiac support.",
keywords = "Follow-up studies, Graft survival, Heart failure/surgery, Heart trans-plantation/methods/physiol-ogy, Heterotopic, HLA antigens/analysis, Reoperation, Survival analysis, Time factors, Transplant recipients, Transplantation, Treatment outcome",
author = "Godfrey, {Elizabeth L.} and Kueht, {Michael L.} and Abbas Rana and Frazier, {O. H.}",
year = "2019",
month = "6",
doi = "10.14503/THIJ-17-6544",
language = "English (US)",
volume = "46",
pages = "199--202",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "3",

}

TY - JOUR

T1 - The man with 2 hearts

T2 - 25 years from heterotopic to orthotopic heart transplantation

AU - Godfrey, Elizabeth L.

AU - Kueht, Michael L.

AU - Rana, Abbas

AU - Frazier, O. H.

PY - 2019/6

Y1 - 2019/6

N2 - Substantial technological advances in mechanical circulatory support have caused a shift in the management of end-stage heart failure. From the 1970s through the 1990s, heterotopic heart transplantation was routinely performed in patients in whom orthotopic transplantation was likely to fail. Heterotopic heart transplantation is now performed less often because modern mechanical circulatory assist devices are routinely used as bridges to orthotopic transplantation; regardless, the operation has helped numerous patients who would not otherwise have received adequate allografts. We describe the case of a man with idiopathic nonischemic cardiomyopathy who, at age 17, was given an ABO-and size-matched heterotopic allograft that was a complete human leukocyte antigen mismatch. The graft functioned normally for 20 years until the patient had a myocardial infarction that necessitated placement of a coronary artery stent. Subsequent treatments involved many interventions, including insertion of an intra-aortic balloon pump, medical therapy for heart failure, implantation of a total artificial heart, and, ultimately, orthotopic transplantation. To our knowledge, our patient is the longest surviving recipient of a heterotopic heart transplant, with a remarkable 25-year graft survival despite poor histocompatibility and an almost complete lack of native heart function. The strategies used for his treatment make him a living case study that can add valuable information to the history of cardiac support.

AB - Substantial technological advances in mechanical circulatory support have caused a shift in the management of end-stage heart failure. From the 1970s through the 1990s, heterotopic heart transplantation was routinely performed in patients in whom orthotopic transplantation was likely to fail. Heterotopic heart transplantation is now performed less often because modern mechanical circulatory assist devices are routinely used as bridges to orthotopic transplantation; regardless, the operation has helped numerous patients who would not otherwise have received adequate allografts. We describe the case of a man with idiopathic nonischemic cardiomyopathy who, at age 17, was given an ABO-and size-matched heterotopic allograft that was a complete human leukocyte antigen mismatch. The graft functioned normally for 20 years until the patient had a myocardial infarction that necessitated placement of a coronary artery stent. Subsequent treatments involved many interventions, including insertion of an intra-aortic balloon pump, medical therapy for heart failure, implantation of a total artificial heart, and, ultimately, orthotopic transplantation. To our knowledge, our patient is the longest surviving recipient of a heterotopic heart transplant, with a remarkable 25-year graft survival despite poor histocompatibility and an almost complete lack of native heart function. The strategies used for his treatment make him a living case study that can add valuable information to the history of cardiac support.

KW - Follow-up studies

KW - Graft survival

KW - Heart failure/surgery

KW - Heart trans-plantation/methods/physiol-ogy

KW - Heterotopic

KW - HLA antigens/analysis

KW - Reoperation

KW - Survival analysis

KW - Time factors

KW - Transplant recipients

KW - Transplantation

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85074414750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074414750&partnerID=8YFLogxK

U2 - 10.14503/THIJ-17-6544

DO - 10.14503/THIJ-17-6544

M3 - Article

C2 - 31708703

AN - SCOPUS:85074414750

VL - 46

SP - 199

EP - 202

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 3

ER -